Phase II Study of Neoadjuvant Chemotherapy With Doxorubicin Followed by Docetaxel-Cisplatin in Locally Advanced Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center Identifier:
First received: October 1, 2007
Last updated: May 26, 2012
Last verified: May 2012
Phase II study of neoadjuvant chemotherapy with Doxorubicin followed by Docetaxel-Cisplatin in locally advanced breast cancer

Condition Intervention
Breast Cancer
Drug: Doxorubicin, Docetaxel, Cisplatin

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by King Faisal Specialist Hospital & Research Center:

Primary Outcome Measures:
  • Effectiveness [ Time Frame: overall ] [ Designated as safety issue: No ]

Enrollment: 10
Study Start Date: September 2007
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm 1
Doxorubicin, Docetaxel, Cisplatin
Drug: Doxorubicin, Docetaxel, Cisplatin
Doxorubicin, Docetaxel, Cisplatin


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with locally advanced breast cancer

Exclusion Criteria:

  • Patients with metastatic breast cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00538525

Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Principal Investigator: Adnan Ezzat, MD KFSH&RC, Riyadh, Saudi Arabia
  More Information

No publications provided

Responsible Party: King Faisal Specialist Hospital & Research Center Identifier: NCT00538525     History of Changes
Other Study ID Numbers: RAC#2011-022
Study First Received: October 1, 2007
Last Updated: May 26, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Enzyme Inhibitors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Radiation-Sensitizing Agents
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Tubulin Modulators processed this record on November 30, 2015